PROGRAM CHAIRS
W. Timothy Garvey, MD
University Professor
School of Health Professions
Department of Nutritional Sciences
University of Alabama
Birmingham, AL
Luca Busetto, MD
Associate Professor of Internal Medicine
Department of Medicine
University of Padova
Padova, Italy
PROGRAM OVERVIEW
This enduring symposium is designed to help healthcare professionals understand that obesity is a prevalent, complex, progressive and relapsing chronic disease, characterized by abnormal or excessive body fat (adiposity), that impairs health. Going beyond BMI in the diagnosis of individuals with obesity and initiating the discussion with patients about this chronic condition will support the incorporation of shared decision-making in treatment goal setting, which is so critical for success. While evidence-based strategies for the management of people with obesity can include medical nutrition therapy, physical activity, psychological interventions, surgery, this program will focus on pharmacotherapy. Along with didactic, evidence-based instruction, this activity will include case studies with Q&A to provide practice identifying patients who would benefit from obesity diagnosis and treatment, ultimately improving outcomes of patients affected by this complex, chronic disease.
TARGET AUDIENCE
This educational activity is intended for primary care physicians on a global level, particularly in Germany, Italy, Spain, France, China, Japan, Brazil, UAE, and Saudi Arabia.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize obesity as a chronic condition that would benefit from clinical intervention and diagnose it in a timely and accurate manner
- Detail the efficacy and tolerability of established and emerging anti-obesity medications to integrate them into therapeutic algorithms based on clinical evidence
- Apply effective strategies to overcome workflow barriers within the healthcare system when managing obesity to improve coordinated care
- Elaborate on strategies for patient-centered, shared decision making that includes educational and motivational interactions with people with obesity
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
EACCME Credit Designation Statement
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at [email protected]
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| W. Timothy Garvey, MD | Reports that he has served on the advisory boards for Allurion, Alnylam, Boehringer Ingelheim, Eli Lilly, Fractyl Health, Inogen, Merck, Novo Nordisk, Pfizer, and Zealand Pharma. In addition, he has conducted contracted research for Eli Lilly, Epitomee, Neurovalens, Novo Nordisk, and Pfizer. Dr. Garvey has served as a consultant of the advisory board for the non-profit Milken Foundation. |
| Luca Busetto, MD | Reports that he has received consulting fees from Boehringer Ingelheim, Bruno Farmaceutici, Eli Lilly, Novo Nordisk, and Pfizer. In addition, he has served on speakers bureaus for PronoKal and Rhythms Pharmaceuticals. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Dave Chatman, Medical Director for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 21, 2024
EXPIRATION DATE: June 21, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
